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Abstract
Aims/hypothesis Glucagon-like peptide 1 (GLP-1) receptor
(GLP-1R) agonism, used in the treatment of type 2 diabetes,
has recently been shown to increase thermogenesis via the
brain. As brown adipose tissue (BAT) produces heat by burn-
ing triacylglycerol (TG) and takes up glucose for de novo
lipogenesis, the aim of this study was to evaluate the potential
of chronic central GLP-1R activation by exendin-4 to facili-
tate clearance of lipids and glucose from the circulation by
activating BAT.
Methods Lean and diet-induced obese (DIO) C57Bl/6J mice
were used to explore the effect of a 5 day intracerebroventric-
ular infusion of the GLP-1 analogue exendin-4 or vehicle on
lipid and glucose uptake by BAT in both insulin-sensitive and
insulin-resistant conditions.
Results Central administration of exendin-4 in lean mice in-
creased sympathetic outflow towards BAT and white adipose
tissue (WAT), resulting in increased thermogenesis as evi-
denced by increased uncoupling protein 1 (UCP-1) protein
levels and decreased lipid content, while the uptake of TG-
derived fatty acids was increased in both BAT and WAT.
Interestingly, in DIO mice, the effects on WAT were blunted,
while exendin-4 still increased sympathetic outflow towards
BAT and increased the uptake of plasma TG-derived fatty
acids and glucose by BAT. These effects were accompanied
by increased fat oxidation, lower plasma TG and glucose con-
centrations, and reduced body weight.
Conclusions/interpretation Collectively, our results suggest
that BAT activation may be a major contributor to the
glucose- and TG-lowering effects of GLP-1R agonism.
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Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) ago-
nists, such as exendin-4, have been used in the treatment of
type 2 diabetes; they increase glucose-dependent insulin se-
cretion, regulate gastric emptying and reduce food intake and
body weight [1]. At least some of these actions are mediated
through neuroendocrine mechanisms, as shown by rodent
studies, consistent with the notion that GLP-1R is highly
expressed in the hypothalamus. Intracerebroventricular
(i.c.v.) administration of GLP-1 reduces food intake and body
weight [2, 3]. Moreover, the central GLP-1R signalling sys-
tem is linked to the control of peripheral glucose metabolism
by inhibiting non-insulin-mediated glucose uptake by muscle
and increasing insulin secretion from the pancreas [4, 5]. Pre-
viously, we have shown that subcutaneous GLP-1 treatment
reduces hepatic glucose production in mice, partly through
central GLP-1R signalling [6]. Hence, one of the functions
of the central GLP-1R system is the modulation of the meta-
bolic activity in peripheral organs that are crucial for the main-
tenance of energy homeostasis.
Brown adipose tissue (BAT) is a regulator of overall energy
homeostasis by combusting triacylglycerol (TG) and glucose
into heat. Enhancement of the thermogenic capacity of BAT
induces weight loss through increased energy expenditure [7,
8] and lowers the plasma levels of TG and glucose. In fact,
BAT activation can correct hyperlipidaemia [9] and
hyperglycaemia [10] by increased uptake of TG-derived fatty
acids [11] and glucose from plasma. Recently, it has been
shown that activation of central GLP-1R increases thermogen-
esis in BATand induces browning within white adipose tissue
(WAT), and that this correlates with increased expression of
genes required for thermogenesis, including uncoupling
protein-1 [12, 13]. While these findings suggest an important
role of the central GLP-1R system in BAT activation, the
effect of central GLP-1R activation on lipid and glucose con-
trol by BAT has not yet been investigated. Furthermore, al-
though GLP-1R agonists are implemented to treat type 2 dia-
betes, the responsiveness of the central GLP-1R system to
activate BAT to take up TG-derived fatty acids and glucose
under central insulin resistance [14] is unknown.
The aim of this study was to evaluate the potential of acti-
vating central GLP-1R by exendin-4 to facilitate clearance of
lipids and glucose from the circulation by activating BAT,
under both insulin-sensitive and insulin-resistant conditions
in diet-induced obese (DIO) C57Bl/6J mice.
Methods
Animals For all experiments, 20-week-old male C57Bl/6J
mice (Charles River, Saint-Germain-Nuelles, France) were
used, housed with a regular 12:12 h light/dark cycle in a
temperature- and humidity-controlled environment, with free
access to food and water unless noted otherwise. For diet-
induced obesity, mice were fed a high-fat diet (44% energy
derived from bovine fat; Hope Farms, Woerden, the Nether-
lands) for 12 weeks, starting at 8 weeks of age. All animal
experiments were performed in accordance with the regula-
tions of the Dutch law on animal welfare, and the Institu-
tional Ethics Committee for Animal Procedures, Leiden Uni-
versity Medical Center, Leiden, the Netherlands, approved
the protocol.
Intracerebroventricular surgery and treatmentMice were
randomised based on bodyweight, anaesthetised and cannulas
(Brain Infusion Kit 3, ALZET Cupertino, CA, USA) were
stereotactically implanted into the left lateral ventricle of the
brain (coordinates −0.45 mm anteroposterior, −1.00 mm lat-
eral and 2.50 mm dorsoventral from bregma). Osmotic
minipumps (Model 1004, Alzet, CA, USA) attached to the
cannula via a catheter were implanted subcutaneously on the
back, slightly posterior to the scapulae. The catheter connect-
ed to the osmotic minipump was filled with artificial cerebro-
spinal fluid (aCSF; Harvard Apparatus, Holliston, MA, USA)
to delay the start of drug delivery by 2 days. The minipump
assured continuous delivery of 0.75 nmol/day exendin-4
(Bachem, Weil am Rhein, Germany) dissolved in aCSF or
aCSF only. The dose of exendin-4 was expected to suppress
food intake. Therefore, an aCSF-receiving pair-fed control
group (restricted to the same amount of food each day as
consumed by the i.c.v. exendin-4-infused mice) was also in-
cluded. Because of the inclusion of a pair-fed group, blinding
to group assignment was not feasible. Body weight and food
intake were measured daily. One lean mouse (assigned to
exendin-4 group) and three obese mice (assigned to control
group) were excluded from the study because of complica-
tions after surgery. After 5 days of intervention, TG and glu-
cose clearance was determined as described below.
Triacylglycerol and glucose clearance Triacylglycerol-rich
lipoprotein (TRL)-like particles were prepared from 100 mg
of total lipid including glycerol trioleate (triolein; 70 mg), egg
yolk phosphatidylcholine (22.7 mg), lysophosphatidylcholine
(2.3 mg), cholesteryl oleate (3.0 mg) and cholesterol (2.0 mg),
with addition of glycerol tri[3H]oleate ([3H]TO) (3.7 MBq).
The emulsion was sonicated and fractionated by consecutive
density gradient ultracentrifugation steps [15]. The emulsion
fraction containing TRL-like particles with an average size
80 nmwas isolated and mixed with 2-[1-14C]deoxy-D-glucose
([14C]DG) in a 3:1 ratio based on radioactive count. Emul-
sions were stored at 4°C under argon and used for in vivo
kinetic experiments within 5 days following preparation.
Animals were fasted for 4 h. At t=0, blood was drawn via
the tail vein to determine, via enzymatic assays, basal plasma
TG (Roche Molecular Biochemicals, Indianapolis, IN, USA)
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and glucose (Instruchemie, Delfzijl, the Netherlands). Mice
then received an i.v. injection of TRL-like particles (1 mg
TG) and [14C]DG. Blood samples were taken from the tail
vein at 2, 5, 10 and 15 min after injection, and plasma 3H
and 14C activities were counted. After the last blood sample,
the mice were killed, perfused via the heart with ice-cold PBS
and various organs were collected. Organs were dissolved
overnight at 60°C in Tissue Solubilizer (Amersham Biosci-
ences, Roosendaal, the Netherlands), and 3H and 14C activities
were counted. Uptake of [3H]TO- and [14C]DG-derived radio-
activity by the organs was calculated from the 3H and 14C
activities in each organ and expressed as percentage of
injected dose per g wet tissue weight.
Body composition After the treatment period, body com-
position (lean and fat mass) was determined in conscious
DIO mice using an EchoMRI-100 (EchoMRI, Houston,
TX, USA).
Indirect calorimetry During the treatment period of the DIO
mice, oxygen uptake (V
⋅
O2), carbon dioxide production
(V
⋅
CO2) and physical activity were measured in metabolic
cages (LabMaster System, TSE Systems, Bad Homburg, Ger-
many). The average respiratory exchange ratio (RER), energy
expenditure and carbohydrate and fat oxidation rates were
calculated from day 1 to day 4 of treatment, as described
previously [16].
Histology Formalin-fixed paraffin-embedded interscapular
BAT (iBAT) and subcutaneous WAT (sWAT) tissue sections
(5 μm) were stained with haematoxylin and eosin (H&E)
using standard protocols. For staining of UCP-1 and tyrosine
hydroxylase (TH), sections were dewaxed, rehydrated and
treated with peroxidase. Antigen retrieval was accomplished
in 10 mmol/l citrate buffer (pH=6.0). Slides were blocked
with normal goat serum (UCP-1) or BSA (TH) and incubated
overnight at 4°C with anti-UCP-1 antibodies (1:4,000;
Ab10983; Abcam, Cambridge, UK) or anti-TH antibodies
(1:2,000; Ab112; Abcam). Next, sections were incubated for
30 min with biotinylated goat α-rabbit secondary antibodies
(UCP-1; 1:600; Vector Labs, Burlingame, CA, USA) or
DAKO EnVision anti-rabbit antibodies (DAKO, Glostrup,
Denmark). Immunostaining was amplified and visualised
using the Elite ABC Nova Red kit (Vector Labs).
Counterstaining was performed with Mayer’s haematoxylin
(1:4). The areas occupied by intracellular lipid vacuoles,
UCP-1 and TH protein were quantified using ImageJ.
Statistical analysis Differences between groups were deter-
mined with the Kruskal–Wallis non-parametric test. When
significant differences were found, the Mann–Whitney non-
parametric test was used as a post hoc test to determine differ-
ences between two independent groups. Serum decay in the
clearance experiment was analysed using repeated-
measurements ANOVAwith Tukey’s post hoc test. A p value
of <0.05 was considered statistically significant. Data are
presented as mean±SD.
Results
Central GLP-1R activation decreases body weight and in-
duces BAT activation in lean C57Bl/6J mice Intracerebro-
ventricular infusion of exendin-4 in lean C57Bl/6J mice de-
creased body weight compared with controls (Fig. 1a, b), and
this was accompanied by a reduced food intake (Fig. 1c), both
of which are well-known effects of activation of the central
GLP-1R system [3, 17]. Reduction of food intake per se, as
shown by the control mice that were pair fed with the exendin-
4-treated mice (Fig. 1c), resulted in a reduction in body weight
compared with controls that was delayed compared with that
evoked by exendin-4 (Fig. 1a).
As central GLP-1 infusion increases sympathetic outflow
towards BAT and WAT and subsequently stimulates thermo-
genesis [12, 13, 18], we analysed the expression of TH, a
marker for activity of noradrenergic (norepiphrenergic) nerve
fibres [19]. Exendin-4 increased the TH content in both iBAT
(+103%, p<0.01) and sWAT (+331%, p<0.05) compared
with controls (Fig. 1d, e). This increased sympathetic nervous
system (SNS) signalling was accompanied by enhanced ther-
mogenic capacity, as exendin-4 increased UCP-1 protein con-
tent in iBAT (+44%, p<0.01) and sWAT (+142%, p<0.05)
compared with the control group (Fig. 1f, g), indicating more
active BAT as well as browning of WAT. Reduction of food
intake per se evoked similar increases in UCP-1 protein con-
tent in both BAT and WAT, but it was apparently independent
of sympathetic input, which suggests the involvement of other
pathways. The effects of exendin-4 on UCP-1 content were
accompanied by a decreased lipid droplet content in iBAT
(−67%, p<0.001) and sWAT (−53%, p<0.05) (Fig. 1h, i),
probably as activation of BAT results in combustion of intra-
cellular lipid stores as well as browning of WAT. The lipid
content in iBAT was reduced to a greater extent in exendin-
4-treated mice than in food-restricted mice (−46%, p<0.05),
which coincided with a higher level of TH, reflecting higher
SNS activity towards BAT induced by exendin-4.
Central GLP-1R activation enhances uptake of plasma
TG-derived fatty acids and glucose by BAT and browns
WAT in lean C57Bl/6J mice Subsequently, we tested our
hypothesis that BAT activated during chronic GLP-1R ac-
tivation is a major contributor to the plasma clearance of
TG and glucose. To this end, mice were injected i.v. with
[3H]TO-labelled TRL-like emulsion particles and [14C]DG.
Indeed, exendin-4 accelerated the clearance of [3H]TO
from plasma (Fig. 2a). This enhanced clearance was the
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result of a greatly increased uptake of [3H]TO-derived ac-
tivity by iBAT (+276%, p<0.001; Fig. 2b). In addition,
exendin-4 enhanced the uptake of [3H]TO-derived activity
by both sWAT (+111%, p<0.01) and gonadal (g)WAT
(+138%, p<0.05) compared with the control group, corre-
sponding to the browning observed in these WAT depots.
The pair-fed animals showed similar results for [3H]TO
kinetics as the exendin-4-treated group. Plasma clearance
was increased (Fig. 2a), relating to a marked increase in
the uptake of 3H activity by iBAT compared with control-
infused animals (+314%, p<0.001; Fig. 2b). In addition,
the uptake by sWAT was increased (+194%, p<0.05),
whereas there was no significant effect on uptake by gWAT
(+109%, p=0.20) in pair-fed conditions.
Similar to plasma [3H]TO clearance, chronic infusion of
exendin-4 accelerated the clearance of [14C]DG from plasma
(Fig. 2c). This enhanced clearance from the circulation was
the result of an increased uptake of [14C]DG by iBAT
(+142%, p<0.01) and skeletal muscle (+40%, p<0.05) com-
pared with controls (Fig. 2d). Interestingly, while the uptake
of [3H]TO-derived activity by BAT in pair-fed mice was
increased to a similar extent as in exendin-4 treated animals,
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b cFig. 1 Central GLP-1R
activation decreases body weight
and food intake and induces
activation of BAT in lean mice.
Mice were treated for 5 days with
i.c.v. exendin-4 (n=8) or vehicle
(control n=9, pair-fed n=6). On a
daily basis, body weight (a, b)
and food intake (c) were
monitored. Samples of BAT and
WATwere collected and stained
for TH and UCP-1.
Representative pictures and
quantification of TH (d, e), UCP-
1 (f, g) and lipid droplet content
with H&E staining (h, i) are
shown. Values are mean±SD.
*p<0.05, **p<0.01 and
***p<0.001 compared with
control; †p<0.01 compared with
pair-fed control. White bars,
control; black bars, exendin-4;
grey bars, pair-fed control
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To rule out that the effects of i.c.v. administered exendin-4
on the uptake of TG-derived fatty acids and glucose by BAT
were caused by leakage of exendin-4 into the circulation, we
next administered exendin-4 peripherally at the same dose as
administered centrally. Peripheral exendin-4 treatment for
5 days delivered via subcutaneous minipumps did not en-
hance the uptake of [3H]TO-derived activity (Fig. 2e) or
[14C]DG (Fig. 2f) by BAT. Peripheral exendin-4 only slightly
increased the uptake of [3H]TO-derived activity by gWAT,
possibly via a direct effect of GLP-1R signalling on white
adipocyte formation [20].
Central GLP-1R activation decreases bodyweight, plasma
TG and glucose levels, and shifts combustion from carbo-
hydrates towards fat in DIO C57Bl/6J mice To determine
whether chronic i.c.v. exendin-4 infusion still leads to an
increased uptake of plasma TG-derived fatty acids and glu-
cose via BAT when obesity and insulin resistance have de-
veloped, we next explored the effects of central GLP-1R
activation after 12 weeks of high-fat feeding. In DIO mice,
continuous infusion of exendin-4 for 5 days decreased body
weight compared with control-infused mice (Fig. 3a), which
could only partly be attributed to reduced food intake
(Fig. 3b) as the reduction in body weight was greater than
in pair-fed controls. Determination of body composition
showed that exendin-4 and pair feeding decreased body
weight because of a selective decrease in fat mass compared
with controls (Fig. 3c). Furthermore, plasma TG and glucose
levels were both decreased from baseline values in the
exendin-4-infused mice at the end of the treatment period
(Table 1). In the pair-fed mice, plasma glucose levels were
reduced from baseline values, but remained significantly
higher than in the exendin-4-treated mice.
Indirect calorimetry showed that the decreased fat mass in
the exendin-4-infused DIO mice was accompanied by an
increased fat oxidation (Fig. 3d) at the expense of carbohy-
drate oxidation (Fig. 3e). This was also reflected in a de-
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Fig. 2 Central GLP-1R
activation increases uptake of
plasma TG-derived fatty acids
and glucose by BAT in lean mice.
Mice were treated for 5 days via
i.c.v. (a–d) or i.v. (e–f) routes with
exendin-4 (n=8) or vehicle
(control n=9, pair-fed n=6). After
treatment, mice were injected
with [3H]TO-labelled particles
and [14C]DG. Plasma 3H activity
(a) and 14C activity (c) were
plotted relative to the injected
dose. At 15 min after injection,
organs were isolated and uptake
of 3H activity (b, e) and 14C
activity (d, f) was determined.
Values are mean±SD. *p<0.05,
**p<0.01 and ***p<0.001
compared with control. †p<0.05
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shift in nutrient combustion. Of note, exendin-4 reduced
total energy expenditure (Fig. 3g) and decreased physical
activity (Fig. 3h). Pair feeding also increased fat oxidation
and decreased carbohydrate oxidation compared with the
controls, but these effects were less pronounced than those
of exendin-4. This implies that the effects of exendin-4 on
energy metabolism are only partly caused by reduced food
intake in DIO mice.
Central GLP-1R activation increases BAT thermogenesis,
but does not induce browning of WAT in DIO C57Bl/6J
mice Under high-fat-fed conditions, i.c.v. exendin-4 treat-
ment still increased SNS output towards BAT compared with
controls, reflected by increased TH content (sBAT +59%,
p<0.05 [not shown]; iBAT +107%, p<0.01, Fig. 4a, b)
and increased UCP-1 protein content (sBAT +62% [not
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Fig. 3 Central GLP-1R
activation decreases body weight
and shifts combustion from
carbohydrates towards fat in DIO
mice. After 12 weeks of high-fat
feeding, mice were treated for
5 days with i.c.v. exendin-4 (n=
10) or vehicle (control n=6, pair-
fed n=9). Body weight gain (a)
and food intake (b) were
determined. Lean (crossed area)
and fat (no cross) mass were
measured (c). During the
treatment period, mice were
housed in metabolic cages. Fatty
acid oxidation (d), carbohydrate
oxidation (e), RER (f) and energy
expenditure (g) were calculated
from O2 uptake and CO2
excretion. (h) Magnitude of
physical activity in arbitrary units.
Values are mean±SD. *p<0.05,
**p<0.01 and ***p<0.001
compared with control. †p<0.05
and †††p<0.001 compared with
pair-fed control. White
bars/continuous lines, control;
black bars/dotted lines, exendin-
4; grey bars/dashed lines, pair-fed
controls. AU, arbitrary units; CH,
carbohydrate; EE, energy
expenditure; FA, fatty acid
Table 1 Central GLP-1R activation decreases plasma TG and glucose
levels in DIO mice
Variable Control Exendin-4 Pair-fed control
TG (mmol/l)
Start 0.7±0.1 0.7±0.1 0.6±0.1
End 0.7±0.5 0.5±0.2* 0.6±0.4
Glucose (mmol/l)
Start 11.3±0.8 11.6±1.1 11.4±1.1
End 10.6±0.9 4.5±1.2*** , ††† 7.4±1.1***
After 12weeks of high-fat feeding, mice were treated for 5 dayswith i.c.v.
exendin-4 (n=10) or vehicle (control n=6, pair-fed n=9). Blood was
collected before and after treatment by tail bleeding after 4 h of fasting
and plasma TG and glucose were determined
Values are mean±SD
*p<0.05 and ***p<0.001 compared with baseline; †††p<0.001 com-
pared with pair-fed control
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indicative of more active BAT. As a consequence, lipid
droplet content was decreased in the exendin-4-treated ani-
mals compared with controls (sBAT −49%, p<0.05 [not
shown]; iBAT −41%, p<0.01, Fig. 4e, f). Pair feeding did
not affect TH expression in BAT (Fig. 4a, b), slightly in-
creased UCP-1 protein content (Fig. 4c, d) and slightly de-
creased lipid content (Fig. 4e, f) compared with controls. In
contrast to the lean mice, infusion of exendin-4 in DIO mice
did not induce browning of WAT as evidenced by unaffected
TH expression, UCP-1 protein and lipid content.
Central GLP-1R activation enhances TG and glucose
clearance by BAT in DIO C57Bl/6J mice Similar to lean
mice, chronic i.c.v. infusion of exendin-4 in DIO mice accel-
erated the plasma clearance of [3H]TO (Fig. 5a) and [14C]DG
(Fig. 5c). This was accompanied by a selectively increased
uptake of [3H]TO-derived activity and [14C]DG by iBAT (+
291%, p<0.001 and +482%, p<0.001, respectively) and
sBAT (+217%, p<0.01 and +247%, p<0.001, respectively)
(Fig. 5b, d). Despite the lack of evidence for browning of
WAT, exendin-4 enhanced the uptake of both [3H]TO-derived
activity and [14C]DG by both sWAT (+146%, p<0.05 and
+93%, p<0.05) and gWAT (+69%, p<0.01 and +82%,
p<0.01). To some extent, the pair-fed animals showed similar
results on [3H]TO and [14C]DG kinetics as the exendin-4
treated mice. Plasma clearance was increased (Fig. 5a, c),
associated with a marked increase in uptake of [3H]TO-de-
rived activity and [14C]DG by iBAT (+170%, p<0.01 and
+482%, p<0.001, respectively) and sBAT (+188%, p<0.001
and +247%, p<0.001, respectively) compared with control-
infused animals (Fig. 5b, d). Interestingly, the uptake of
[3H]TO-derived activity by iBAT and the uptake of [14C]DG
by iBAT and sBAT were significantly lower compared with
the exendin-4-treated mice (−31%, p<0.05, −63%, p<0.01
and −43%, p<0.01, respectively), indicating that exendin-4
exerts its effects partly independent of lowering food intake.
Discussion
In the present study we show that central GLP-1R activation
by exendin-4 increases the plasma clearance of TG and glu-
cose in both lean and DIOC57Bl/6J mice via increased uptake
of TG-derived fatty acids and glucose by BAT, accompanied
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Fig. 4 Central GLP-1R
activation increases TH and UCP-
1 protein levels and decreases
lipid droplet content in BAT in
DIO mice. After 12 weeks of
high-fat feeding, mice were
treated for 5 days with i.c.v.
exendin-4 (n=10) or vehicle
(control n=6, pair-fed n=9). After
treatment, mice were killed and
BATandWATwere collected and
stained for TH and UCP-1.
Staining with H&E was
performed for lipid droplet
content. Representative pictures
and quantification of TH (a, b),
UCP-1 (c, d) and lipid droplet
content (e, f) are shown. Values
are mean±SD. *p<0.05,
**p<0.01 and ***p<0.001
compared with control. †p<0.01
compared with pair-fed control.
White bars, control; black bars,
exendin-4; grey bars, pair-fed
control
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First, we showed that continuous central infusion of the
GLP-1R analogue exendin-4 (5 days, 0.75 nmol/day) evokes
the well-known effect of reducing food intake and body
weight [3, 17]. In addition, central administration of
exendin-4 increased SNS activity towards BAT and WAT, as
evidenced by increased TH and UCP-1 protein content and
lowered lipid content. This corroborates previous findings
demonstrating the essential role of the SNS in BAT and
WAT activation by central GLP-1R signalling [12, 18].
Exendin-4 also caused a robustly accelerated clearance of
plasma TG and glucose, which likely contributed to reduced
plasma TG and glucose concentrations observed in DIOmice.
Strikingly, the uptake of TG-derived activity, presumably
[3H]oleate liberated by lipoprotein lipase (LPL) [11], was
not only increased by BAT but also by WAT, together with
the increase in UCP-1 content indicative of so-called brow-
ning. Although activation of BAT and WAT are likely in-
volved in the observed reduction of plasma TG and glucose
by central exendin-4, further studies are warranted to investi-
gate the quantitative contribution of GLP-1R signalling to-
wards BAT and WAT to the overall metabolic improvements
on GLP-1R agonism.
It has been reported that central GLP-1 infusion reduces the
lipid content of WAT in lean mice but not DIO mice [18],
suggesting that some resistance to the actions of central
GLP-1 is induced in DIO mice. Clearly, this effect is not
desirable for a drug to treat obesity. Therefore, we explored
the effects of chronic central exendin-4 infusion after 12weeks
of high-fat feeding, sufficient to induce obesity and insulin
resistance in this mouse model [21, 22]. Our results show that
under these conditions, chronic central GLP-1R signalling still
improves the clearance of plasma TG and glucose via a ro-
bustly increased uptake by BAT. However, central GLP-1R
agonism did not alter UCP-1 protein content or lipid droplet
content in WAT in DIO mice, consistent with previous find-
ings by Nogueiras et al [18]. It is interesting to speculate on
why, during obesity, WAT is not susceptible to browning on
exendin-4 treatment. Previous studies reported a decreased
sensitivity of white adipocytes to adrenergic stimulation in
obese individuals [23]. However, in our study we also de-
scribe the absence of exendin-4-induced TH expression in
WAT in DIO mice. It is possible that different brain areas
modulate specific BAT and WAT functions. While multiple
tissues are simultaneously sympathetically stimulated during
cold exposure, there are many examples of treatments that
result in differential sympathetic outflow to various types of
tissues (e.g. WAT vs BAT) and even within a type of tissue
(e.g. different WAT pads) [24]. The GLP-1R is widely
expressed through the hypothalamus [25], and exerts effects
via different nuclei. For example, GLP-1R signalling in the
arcuate nucleus regulates glucose metabolism, while it modu-
lates feeding via the paraventricular nucleus [5]. Altogether, it
is likely that GLP-1R signalling and subsequent sympathetic
outflow differ during obesity and lean conditions.
In apparent contrast to the notion that increased BATactiv-
ity is generally correlated with an enhanced total energy ex-
penditure [26], central GLP-1R activation in fact reduced total
energy expenditure, an effect we have observed before during
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Fig. 5 Central GLP-1R
activation increases uptake of
plasma TG-derived fatty acids
and glucose by BAT in DIO mice.
After 12 weeks of high-fat
feeding, mice were treated for
5 days with i.c.v. exendin-4 (n=
10) or vehicle (control n=6, pair-
fed n=9). After treatment, mice
were injected with [3H]TO-
labelled particles and [14C]DG.
Plasma 3H activity (a) and 14C
activity (c) were plotted relative to
the injected dose. At 15 min after
injection, organs were isolated
and uptake of the 3H activity (b)
and 14C activity (d) was
determined. Values are mean±
SD. *p<0.05, **p<0.01 and
***p<0.001 compared with
control. †p<0.05 and ††p<0.01
compared with pair-fed control.
White bars, control; black bars,
exendin-4; grey bars, pair-fed
control
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chronic peripheral exendin-4 treatment [27]. Possibly, the re-
duction in energy intake is compensated by a relative reduc-
tion in energy expenditure. In addition, it appears that chronic
central GLP-1R activation results in a shift from using carbo-
hydrates to fatty acids as an energy source, which is consistent
with previous studies that showed that chronic i.c.v. GLP-1
treatment decreased the respiratory quotient, indicative of a
higher level of fat oxidation by BAT [18, 28]. The exendin-
4-induced decrease in physical activity, resulting from a di-
minished food-seeking behaviour [29], is less likely to con-
tribute to the change in total energy expenditure [30].
From a clinical perspective, the possibility that BAT activity
in humans may be amenable to pharmacological manipulation
by GLP-1R agonism to control insulin sensitivity and body
weight is attractive but, as yet, undemonstrated. Drugs targeting
the GLP-1R system are already widely prescribed for their
incretin properties to treat type 2 diabetes, but they may be
useful in a wider context related to energy balance. The resting
energy expenditure of obese individuals with type 2 diabetes
increases with 1 year of treatment with a combination of met-
formin and exenatide or liraglutide [13]. It is tempting to spec-
ulate that BAT may be activated in these patients. Increasing
our knowledge about the mechanism of action of exendin-4
may add to the (further) development of peptidomimetics in
our battle against obesity and type 2 diabetes.
In conclusion, our results show that chronic central infu-
sion of exendin-4 increases SNS output to enhance BAT ac-
tivity in both lean and DIO C57Bl/6J mice. Via highly active
BAT, the plasma clearance of TG and glucose is accelerated
and body fat content is decreased, which, together with re-
duced food intake, leads to a decrease in body weight. There-
fore, we suggest that GLP-1R agonists via BAT activation
reduce both hyperlipidaemia and hyperglycaemia, and possi-
bly even atherosclerosis [31], in addition to the effects of BAT
activation on obesity.
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